Elasmogen discovering and developing Solomers

Immunology & Inflammation Therapeutics · Biologics & Biosimilars

Overview

Elasmogen is a biopharmaceutical company developing next-generation soloMER™ biologics. We specialize in high-affinity, site-specific treatments for solid-tumor cancers and inflammatory diseases.

Financials

Total raised
$1.7M
Latest round
Venture - Series Unknown
Funding rounds
14
Funding rounds
Round Announced Amount
Venture - Series Unknown 2026 — Details
Venture - Series Unknown 2022 — Details
Venture - Series Unknown 2021 — Details
Venture - Series Unknown 2021 — Details
Grant 2020 $295k Details
Grant 2019 — Details
Venture - Series Unknown 2019 — Details
Grant 2018 — Details
Grant 2018 $557k Details
Venture - Series Unknown 2018 — Details
Venture - Series Unknown 2017 — Details
Grant 2017 $871k Details
Venture - Series Unknown 2016 — Details
Venture - Series Unknown 2015 — Details

Connections

List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors2
Scottish National Investment BankVia a fund
12 portfolio companies: Gresham House, FOR EV, IndiNature and 9 more
BGFVia a fund
405 portfolio companies
Report a mistake